Annexon (ANNX) Other Accumulated Expenses (2019 - 2026)
Annexon (ANNX) posted quarterly Other Accumulated Expenses of $11.0 million for Q1 2026, up 4508.37% year-over-year from $239000.0 in Q1 2025, and down 32.37% quarter-over-quarter from $16.3 million in Q4 2025.
Analysis
Annexon (ANNX) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Annexon's Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $11.0 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 4508.37% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (up 4508.37% YoY), while the FY2025 annual figure was $16.3 million, up 11449.65% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $11.0 million, down from $16.3 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $16.3 million in Q4 2025, with the low at $79000.0 in Q3 2023.
- The 5-year median for Other Accumulated Expenses is $164000.0 (2022), against an average of $3.3 million.
- The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses plunged 94.82% in 2022, then jumped 11449.65% in 2025.
- Annexon's Other Accumulated Expenses stood at $180000.0 in 2022, then fell by 21.67% to $141000.0 in 2023, then changed by 0.0% to $141000.0 in 2024, then surged by 11449.65% to $16.3 million in 2025, then slumped by 32.37% to $11.0 million in 2026.
- Business Quant data shows ANNX's Other Accumulated Expenses at $11.0 million in Q1 2026, $16.3 million in Q4 2025, and $15.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Annexon | 982.93 Mn | 982.93 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.94 Mn |
| Mar 31, 2026 | 11.01 Mn |
| Dec 31, 2025 | 16.29 Mn |
| Sep 30, 2025 | 15.76 Mn |
| Jun 30, 2025 | 21.68 Mn |
| Mar 31, 2025 | 17.41 Mn |
| Dec 31, 2024 | 10.99 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 6.54 Mn |
| Mar 31, 2024 | 4.53 Mn |
| Dec 31, 2023 | 4.03 Mn |
| Sep 30, 2023 | 5.27 Mn |
| Jun 30, 2023 | 5.46 Mn |
| Mar 31, 2023 | 7.51 Mn |
| Dec 31, 2022 | 7.72 Mn |
| Sep 30, 2022 | 7.05 Mn |
| Jun 30, 2022 | 4.16 Mn |
| Mar 31, 2022 | 3.74 Mn |
| Dec 31, 2021 | 2.40 Mn |
| Sep 30, 2021 | 3.17 Mn |